Search

Your search keyword '"Zietman, A.L."' showing total 347 results

Search Constraints

Start Over You searched for: Author "Zietman, A.L." Remove constraint Author: "Zietman, A.L."
347 results on '"Zietman, A.L."'

Search Results

2. Prospective Validation of Single Nucleotide Polymorphisms as Predictors of Gastrointestinal, Genitourinary, and Sexual Patient-Reported Outcomes Following Radiotherapy for Prostate Cancer

3. Prognostic Significance of Pretreatment Immune Cell Infiltration in Muscle Invasive Bladder Cancer Treated with Definitive Chemoradiation: Analysis of NRG RTOG 0524 and 0712

4. Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer

7. Multi-Institutional Matched Comparison of Radical Cystectomy to Trimodality Therapy for Muscle Invasive Bladder Cancer (MIBC)

12. Metastasis-Free Survival, but Not Biochemical Failure, is a Strong Surrogate Endpoint for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601

13. Bladder Preservation with Twice-Daily Radiation plus 5-Flourouracil/Cisplatin or Daily Radiation plus Gemcitabine for MIBC – Updated Results of NRG/RTOG 0712: A Randomized Phase 2 Trial

15. External Validation of Early Quality of Life (QOL) Declines Correlated with Late QOL after Intensity Modulated, Low Dose Rate Brachytherapy, or Stereotactic Radiation for Prostate Cancer within a Prospective Trial

16. The Impact of Persistently Elevated PSA after Prostatectomy in Men with Recurrent Prostate Cancer in NRG Oncology/RTOG 9601

17. Two Years of Anti-Androgen Treatment Increases Other-Cause Mortality in Men Receiving Early Salvage Radiotherapy: A Secondary Analysis of the NRG Oncology/RTOG 9601 Randomized Phase III Trial

19. Integrated Gene Expression Score in Circulating Tumor Cells to Predict Treatment Response in Muscle-Invasive Bladder Cancer

31. Radiation therapy in the management of early stage Hodgkin's disease presenting in later life

33. Selective Bladder Preservation with Twice-Daily Radiation Plus 5-Flourouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Patients with Muscle Invasive Bladder Cancer—Primary Results of NRG/RTOG 0712: A Randomized Phase 2 Multicenter Trial

35. The Impact of MRE11 in Nuclear to Cytoplasmic Ratio on Outcomes in Muscle Invasive Bladder Cancer: an Analysis of NRG/RTOG 8802, 8903, 9506, 9706, 9906, and 0233.

36. Multi-institutional Outcomes of Postprostatectomy Adjuvant Versus Early Salvage Radiation Therapy in Prostate Cancer Patients With Adverse Pathologic Features

40. The Natural History of Nonmuscle-Invasive Bladder Cancer Recurrences After Complete Response to Combined-Modality Organ-Preserving Therapy for Muscle-Invasive Bladder Cancer

41. Dosimetric Validation of Robotic Prostate SBRT With Simultaneous Integrated Dose Escalation to Dominant Intraprostatic Lesion Using a Magnetic Resonance–Based 3D-Printed Prostate Model in an Anthropomorphic Pelvis Phantom

42. Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-Term Results of a Large Institutional Experience

43. Report of NRG Oncology/RTOG 9601, A Phase 3 Trial in Prostate Cancer: Anti-androgen Therapy (AAT) With Bicalutamide During and After Radiation Therapy (RT) in Patients Following Radical Prostatectomy (RP) With pT2-3pN0 Disease and an Elevated PSA

46. Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer

48. Early Quality of Life (QOL) Declines Correlate With Later QOL After Intensity Modulated Radiation Therapy, Low-Dose-Rate Brachytherapy, or Stereotactic Radiation for Prostate Cancer

49. Comparative Effectiveness Analysis of Patient-Reported Quality of Life (QOL) After Stereotactic Body Radiation Therapy as Compared to Intensity Modulated Radiation Therapy or Low-Dose-Rate Brachytherapy up to 2 Years After Treatment

Catalog

Books, media, physical & digital resources